

<b>IRP Lifecycle Validation Checklist: Variation, Renewal etc (Version 1.1)</b>	
<b>1</b>	Applicant's reference (If available)
<b>2</b>	This International Recognition application concerns
<b>3</b>	<b>a</b> Specify the Reference Regulator (RR)
	<b>b</b> If the response to (3a) above is EU Member State, specify the country
<b>4</b>	Specify the route used to obtain the Initial UK/GB application
<b>5</b>	<b>a</b> When was the procedure that this application is reliant on approved by the Reference regulator
	<b>b</b> A declaration that the UK IRP application is for the same product as that approved by the RR is included. The same product means the same qualitative and quantitative composition, same dosage form, same MAH (or company group or 'licensees')
	<b>c</b> A declaration that all iterations of the Reference Regulator assessment reports is included in the dossier
	<b>d</b> All the assessment reports included are listed in Annex I below
<b>6</b>	<b>a</b> Are there any conditions associated with the RR approval
	<b>b</b> If the response to (6a) is Yes details are included in a separate document called m1/eu/10-cover/cc/RR-conditions-VAR.EXT
<b>7</b>	<b>a</b> Are there any proposed conditions for UK/GB approval:
	<b>b</b> If the response to (7a) is Yes details are included in a separate document called m1/eu/10-cover/cc/RR-conditions-VAR.EXT
<b>8</b>	<b>a</b> For Variations, is a new indication being added:
	<b>b</b> Are there differences in the wording of the proposed therapeutic indications for UK/GB and the therapeutic indications approved by the RR
	<b>c</b> If the response to (8b) is Yes, justification for these changes is provided in m1/eu/10-cover/cc/RR-justification-UK-GB-indications-VAR.EXT
<b>9</b>	<b>a</b> For Variations, does the variation impact an ASMF
	<b>b</b> A declaration from the applicant that the ASMF Holder has submitted the Applicant's and Restricted Parts of the ASMF, including approved variations and all iterations of the assessment reports on the Applicant's and Restricted Parts, is included in the dossier

<b>c</b>	A letter for permission of access is included in the dossier	
<b>10 a</b>	Where relevant, are there any differences in the proposed UK RMP compared to the RMP that was approved by the RR	
<b>b</b>	Where there are differences in the proposed safety concerns, additional pharmacovigilance activities or additional risk minimisation measures, brief details are provided in Annex II below	
<b>c</b>	Is the GB/UK specific Annex ( <a href="#">Guidance on pharmacovigilance procedures</a> ) used and included with the RMP in 1.8.2	
<b>11 a</b>	For this variation (or renewal) application, has the same change been approved, withdrawn, refused, or rejected by any other RR? Select all that applies	Approved Withdrawn Refused Rejected
<b>b</b>	Reasons for any withdrawal, refusal or rejection is provided in Annex III below	
<b>12</b>	If the variation application affects the SmPC, labelling and/or package leaflet. Clean and tracked versions has been enclosed as word files in the working documents. All changes in the text, in comparison with the previously approved version of product information, has been marked with track-changes in the highlighted versions	
	Annex I (5d) – List Assessment reports provided.	
	Annex II (10b) – Differences in RMP	
	Annex III (11b) – Reasons for withdrawal, refusal or rejection	